NICE recommends the tablets for adults with moderate to severe fibroid symptoms. Linzagolix is recommended for longer-term treatment, with the dose depending on the patient. For endometriosis, they ...

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.

Evidence-based recommendations on dostarlimab (Jemperli) for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

There is a simple discount patient access scheme for zanidatamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for vorasidenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guidance updates and replaces NICE technology appraisal guidance on ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over (TA1088). Next review: This guidance will be ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Evidence-based recommendations on 12 standardised quality betula verrucosa pollen sublingual lyophilisate (12 SQ-Bet SLIT; Itulazax) for treating moderate to severe allergic rhinitis or conjunctivitis ...

There is a simple discount patient access scheme for nemolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

A fall is 'an unexpected event in which the participants come to rest on the ground, floor, or lower level'. Although falls can occur at any age, they become increasingly common as people get older.

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...